EUVIMEDEUVIMED entdecken
Open Access

Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs

Tori Kinamon, Ursula Waack iD, Mark Needles, Daniel Rubin, Deborah Collyar, Sarah B Doernberg iD, Scott R Evans iD, Toshimitsu Hamasaki, Thomas L Holland, Jessica Howard-Anderson, Henry Chambers, Vance G Fowler und 4 weitere

Clinical Infectious Diseases · 19.07.2024 · 79 (1) · 60-69

DOI: 10.1093/cid/ciae163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 25.03.2024. Verfasst von Tori Kinamon und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Pneumonia, Ventilator-Associated, Anti-Bacterial Agents, Pneumonia, Bacterial. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH, ARLG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Desirability of outcome ranking (DOOR) is an innovative approach to clinical trial design and analysis that uses an ordinal ranking system to incorporate the overall risks and benefits of a therapeutic intervention into a single measurement. Here we derived and evaluated a disease-specific DOOR endpoint for registrational trials for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

Methods

Through comprehensive examination of data from nearly 4000 participants enrolled in six registrational trials for HABP/VABP submitted to the Food and Drug Administration (FDA) between 2005 and 2022, we derived and applied a HABP/VABP specific endpoint. We estimated the probability that a participant assigned to the study treatment arm would have a more favorable overall DOOR or component outcome than a participant assigned to comparator.

Results

DOOR distributions between treatment arms were similar in all trials. DOOR probability estimates ranged from 48.3% to 52.9% and were not statistically different. There were no significant differences between treatment arms in the component analyses. Although infectious complications and serious adverse events occurred more frequently in ventilated participants compared to non-ventilated participants, the types of events were similar.

Conclusions

Through a data-driven approach, we constructed and applied a potential DOOR endpoint for HABP/VABP trials. The inclusion of syndrome-specific events may help to better delineate and evaluate participant experiences and outcomes in future HABP/VABP trials and could help inform data collection and trial design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumonia, Ventilator-AssociatedAnti-Bacterial AgentsPneumonia, BacterialHumansMaleHealthcare-Associated PneumoniaFemaleUnited StatesClinical Trials as TopicCross InfectionTreatment OutcomeMiddle AgedUnited States Food and Drug AdministrationAged

Stichwörter der Autor:innen

DOORantimicrobial therapyclinical trialshospital-acquired bacterial pneumoniaventilator-associated bacterial pneumonia

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
  • Oak Ridge Institute for Science and Education, United States Department of Energy, Oak Ridge, Tennessee, USA.
  • Patient Advocates in Research, Danville, California, USA.
  • Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, California, USA.
  • Biostatistics Center and Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington D.C., USA.

ORCID-Profile: Ursula Waack, Sarah B Doernberg, Scott R Evans

Förderung

  • NIAID NIH HHS
  • NIH
  • ARLG)
  • FDA
  • Basilea Pharmaceutica
  • NIAID
  • Antibacterial Resistance Leadership Group

Zitieren

APA

Kinamon, T., Waack, U., Needles, M., Rubin, D., Collyar, D., Doernberg, S. B., Evans, S. R., Hamasaki, T., Holland, T. L., Howard-Anderson, J., Chambers, H., Fowler, V. G., Nambiar, S., Kim, P., Boucher, H. W., & Gopinath, R. (2024). Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs. Clinical Infectious Diseases, 79(1), 60-69. https://doi.org/10.1093/cid/ciae163

Vancouver

Kinamon T, Waack U, Needles M, Rubin D, Collyar D, Doernberg SB, et al. Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs. Clinical Infectious Diseases. 2024;79(1):60-69. doi:10.1093/cid/ciae163

BibTeX
@article{Kinamon2024,
  author = {Kinamon, Tori and Waack, Ursula and Needles, Mark and Rubin, Daniel and Collyar, Deborah and Doernberg, Sarah B and Evans, Scott R and Hamasaki, Toshimitsu and Holland, Thomas L and Howard-Anderson, Jessica and Chambers, Henry and Fowler, Vance G and Nambiar, Sumati and Kim, Peter and Boucher, Helen W and Gopinath, Ramya},
  title = {Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {79},
  number = {1},
  pages = {60--69},
  doi = {10.1093/cid/ciae163}
}
Kostenlos starten →